Paeds Vivas · rheumatology-musculoskeletal-and-sports
Juvenile idiopathic arthritis: Viva
Branching clinical structured oral on juvenile idiopathic arthritis, covering the ILAR classification with the seven categories and the oligoarticular dominance, the chronic anterior uveitis and the three-monthly slit-lamp screening in the high-risk child, the methotrexate at ten to fifteen milligrams per square metre per week, the etanercept and adalimumab biologics, the Wallace clinically inactive disease criteria, and the treat-to-target TREAT trial.
On this page & tools
Target exams
This is a branching oral built to probe the reasoning that holds the classification, the uveitis and the treat-to-target therapeutics at the centre, and to expose the candidate who has memorised the headline without the safety-critical corners. The questions escalate from the framing to the classification, the uveitis, the methotrexate and the biologics, with deliberate probes into the septic-arthritis mimic and the biologic infection. [2]
Opening question: framing the problem
The examiner opens with the swollen knee for ten weeks and asks: how do you frame this problem in a single sentence, and what is your first step? [2]
A strong answer names the oligoarticular juvenile idiopathic arthritis from the ten-week duration, the morning stiffness and the single joint, and states that the first step is the slit-lamp for the uveitis and the exclusion of the mimics. [2]
Model answer. This child has the oligoarticular juvenile idiopathic arthritis from the arthritis of one joint for more than six weeks in a child under sixteen, with the morning stiffness that improves with activity. The first step is the slit-lamp for the chronic anterior uveitis, because she is young, antinuclear-antibody positive and oligoarticular, which is the highest-risk profile, and the full joint examination and the exclusion of the septic arthritis and the mimics. [1][2]
Probe one: the classification
The examiner presses: describe the ILAR classification, and tell me which subtype is the commonest and what the persistent-versus-extended split means. [1]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References9Show ledgerHide ledger
- [1]Petty RE, Southwood TR, Manners P, et al International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 J Rheumatol, 2004.PMID 14760812
- [2]Ravelli A, Martini A Juvenile idiopathic arthritis Lancet, 2007.PMID 17336654
- [4]Giannini EH, Brewer EJ, Kuzmina N, et al Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial N Engl J Med, 1992.PMID 1549149
- [5]Lovell DJ, Giannini EH, Reiff A, et al Etanercept in children with polyarticular juvenile rheumatoid arthritis N Engl J Med, 2000.PMID 10717011
- [6]Wallace CA, Giannini EH, Spalding SJ, et al Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis Arthritis Rheum, 2012.PMID 22183975
- [7]Wallace CA, Ravelli A, Huang B, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis using the OMERACT filter J Rheumatol, 2006.PMID 16482643
- [8]Constantin T, Foeldvari I, Anton J, et al Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative Ann Rheum Dis, 2018.PMID 29592918
- [9]Nordal E, Rypdal V, Christoffersen T, et al. Incidence and predictors of uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study Pediatr Rheumatol Online J, 2017.PMID 28821293
- [11]Horneff G, Minden K, Rolland C, et al. Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review Pediatr Rheumatol Online J, 2023.PMID 36829225